1201362-27-7

Basic information

• Product Name: 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one
• Synonyms: 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one
• CAS NO: 1201362-27-7
• Molecular Weight: 386.453
• Mol File: 1201362-27-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one(1201362-27-7)
• EPA Substance Registry System: 2-anilino-7-[(1S)-4-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one(1201362-27-7)

Safety Data

• Hazardous Substances Data: 1201362-27-7(Hazardous Substances Data)

Upstream product

• 1201363-02-1 ethyl 2-[4-chloro-2-(phenylamino)pyrimidin-5-yl]-2-methylpropanoate 
• 1228561-05-4 C₉H₁₁NO 
• 479206-19-4 racemic tert-butyl (4-hydroxy-2,3-dihydro-1H-inden-1-yl)carbamate 
• 103-70-8 Formanilid 
• 479206-20-7 1-amino-2,3-dihydro-1H-inden-4-ol 
• 1201362-96-0 C₁₄H₁₉NO₃ 
• 1201363-00-9 ethyl 2-[4-chloro-2-(methylsulfonyl)pyrimidin-5-yl]-2-methylpropanoate 
• 1201362-85-7 ethyl 2-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-methylpropanoate 
• 40731-98-4 4-hydroxy-2,3-dihydroindan-1-one 
• 1201364-16-0 (1S)-4-hydroxy-2,3-dihydro-1H-inden-1-aminium trifluoroacetate 

Relevant articles and documents

Structure guided design of a series of selective pyrrolopyrimidinone MARK inhibitors

The initial structure activity relationships around an isoindoline uHTS hit will be described. Information gleaned from ligand co-crystal structures allowed for rapid refinements in both MARK potency and kinase selectivity. These efforts allowed for the identification of a compound with properties suitable for use as an in vitro tool compound for validation studies on MARK as a viable target for Alzheimer's disease.[Figure presented]